OBJECTIVES: This secondary analysis from the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial examines the effects of lowering low-density lipoprotein cholesterol (LDL-C) with statins alone versus statins plus ezetimibe on common carotid artery intima-media thickness (CIMT) in patients with type 2 diabetes and no prior cardiovascular event. BACKGROUND: It is unknown whether the addition of ezetimibe to statin therapy affects subclinical atherosclerosis. METHODS: Within an aggressive group (target LDL-C <or=70 mg/dl; non-high-density lipoprotein cholesterol <or=100 mg/dl; systolic blood pressure <or=115 mm Hg), change in CIMT over 36 months was compared in diabetic individuals >40 years of age receiving statins plus ezetimibe versus statins alone. The CIMT changes in both aggressive subgroups were compared with changes in the standard subgroups (target LDL-C <or=100 mg/dl; non-high-density lipoprotein cholesterol <or=130 mg/dl; systolic blood pressure <or=130 mm Hg). RESULTS: Mean (95% confidence intervals) LDL-C was reduced by 31 (23 to 37) mg/dl and 32 (27 to 38) mg/dl in the aggressive group receiving statins plus ezetimibe and statins alone, respectively, compared with changes of 1 (-3 to 6) mg/dl in the standard group (p < 0.0001) versus both aggressive subgroups. Within the aggressive group, mean CIMT at 36 months regressed from baseline similarly in the ezetimibe (-0.025 [-0.05 to 0.003] mm) and nonezetimibe subgroups (-0.012 [-0.03 to 0.008] mm) but progressed in the standard treatment arm (0.039 [0.02 to 0.06] mm), intergroup p < 0.0001. CONCLUSIONS: Reducing LDL-C to aggressive targets resulted in similar regression of CIMT in patients who attained equivalent LDL-C reductions from a statin alone or statin plus ezetimibe. Common carotid artery IMT increased in those achieving standard targets. (Stop Atherosclerosis in Native Diabetics Study [SANDS]; NCT00047424).
RCT Entities:
OBJECTIVES: This secondary analysis from the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial examines the effects of lowering low-density lipoprotein cholesterol (LDL-C) with statins alone versus statins plus ezetimibe on common carotid artery intima-media thickness (CIMT) in patients with type 2 diabetes and no prior cardiovascular event. BACKGROUND: It is unknown whether the addition of ezetimibe to statin therapy affects subclinical atherosclerosis. METHODS: Within an aggressive group (target LDL-C <or=70 mg/dl; non-high-density lipoprotein cholesterol <or=100 mg/dl; systolic blood pressure <or=115 mm Hg), change in CIMT over 36 months was compared in diabetic individuals >40 years of age receiving statins plus ezetimibe versus statins alone. The CIMT changes in both aggressive subgroups were compared with changes in the standard subgroups (target LDL-C <or=100 mg/dl; non-high-density lipoprotein cholesterol <or=130 mg/dl; systolic blood pressure <or=130 mm Hg). RESULTS: Mean (95% confidence intervals) LDL-C was reduced by 31 (23 to 37) mg/dl and 32 (27 to 38) mg/dl in the aggressive group receiving statins plus ezetimibe and statins alone, respectively, compared with changes of 1 (-3 to 6) mg/dl in the standard group (p < 0.0001) versus both aggressive subgroups. Within the aggressive group, mean CIMT at 36 months regressed from baseline similarly in the ezetimibe (-0.025 [-0.05 to 0.003] mm) and nonezetimibe subgroups (-0.012 [-0.03 to 0.008] mm) but progressed in the standard treatment arm (0.039 [0.02 to 0.06] mm), intergroup p < 0.0001. CONCLUSIONS: Reducing LDL-C to aggressive targets resulted in similar regression of CIMT in patients who attained equivalent LDL-C reductions from a statin alone or statin plus ezetimibe. Common carotid artery IMT increased in those achieving standard targets. (Stop Atherosclerosis in Native Diabetics Study [SANDS]; NCT00047424).
Authors: B V Howard; D C Robbins; M L Sievers; E T Lee; D Rhoades; R B Devereux; L D Cowan; R S Gray; T K Welty; O T Go; W J Howard Journal: Arterioscler Thromb Vasc Biol Date: 2000-03 Impact factor: 8.311
Authors: Anne B Rossebø; Terje R Pedersen; Kurt Boman; Philippe Brudi; John B Chambers; Kenneth Egstrup; Eva Gerdts; Christa Gohlke-Bärwolf; Ingar Holme; Y Antero Kesäniemi; William Malbecq; Christoph A Nienaber; Simon Ray; Terje Skjaerpe; Kristian Wachtell; Ronnie Willenheimer Journal: N Engl J Med Date: 2008-09-02 Impact factor: 91.245
Authors: D H Blankenhorn; R H Selzer; D W Crawford; J D Barth; C R Liu; C H Liu; W J Mack; P Alaupovic Journal: Circulation Date: 1993-07 Impact factor: 29.690
Authors: M J Roman; P S Saba; R Pini; M Spitzer; T G Pickering; S Rosen; M H Alderman; R B Devereux Journal: Circulation Date: 1992-12 Impact factor: 29.690
Authors: B V Howard; E T Lee; L D Cowan; R B Devereux; J M Galloway; O T Go; W J Howard; E R Rhoades; D C Robbins; M L Sievers; T K Welty Journal: Circulation Date: 1999-05-11 Impact factor: 29.690
Authors: Amy M West; Justin D Anderson; Craig H Meyer; Frederick H Epstein; Hongkun Wang; Klaus D Hagspiel; Stuart S Berr; Nancy L Harthun; Joseph M DiMaria; Jennifer R Hunter; John M Christopher; Joshua D Chew; Gabriel B Winberry; Christopher M Kramer Journal: Atherosclerosis Date: 2011-04-16 Impact factor: 5.162
Authors: Dominic Chow; Huichao Chen; Marshall J Glesby; Anthony Busti; Scott Souza; Janet Andersen; Sharon Kohrs; Julia Wu; Susan L Koletar Journal: AIDS Date: 2009-10-23 Impact factor: 4.177